| Keywords: |
survival; disease-free survival; survival analysis; cancer surgery; treatment failure; gene mutation; methylation; promoter region; genetics; fatigue; mortality; salvage therapy; cisplatin; fluorouracil; cancer combination chemotherapy; cancer risk; note; adjuvant therapy; cancer radiotherapy; disease free survival; chemotherapy, adjuvant; radiotherapy, adjuvant; research design; temozolomide; outcome assessment; brain tumor; follow up; glioma; methodology; brain neoplasms; antineoplastic agent; cancer diagnosis; salpingooophorectomy; colorectal cancer; chromosome 1; chromosome 19; dacarbazine; progression free survival; quality of life; ovary cancer; breast cancer; mastectomy; randomized controlled trial; antineoplastic combined chemotherapy protocols; epidermal growth factor receptor; randomized controlled trials as topic; editorial; alkylating agent; vincristine; pathology; brca1 protein; brca2 protein; heterozygote; breast reconstruction; cetuximab; tumor marker; dna methylation; lomustine; procarbazine; time; time factors; irinotecan; panitumumab; molecular marker; gene expression regulation; insomnia; gene expression regulation, neoplastic; cpg island; promoter regions, genetic; adjuvant chemotherapy; genetic susceptibility; gene identification; tumor suppressor proteins; antineoplastic agents, alkylating; drug derivative; dna repair enzymes; cancer relapse; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; chromosomes, human, pair 19; anaplastic glioma; cancer epidemiology; oxaliplatin; risk reduction; k ras protein; dna methyltransferase; mgmt protein, human; pcv protocol; polydeoxyribonucleotide synthase; tumor suppressor protein; breast metastasis; forest; recognition; sleep disorder; tree; chromosome deletion; chromosomes, human, pair 1; dna modification methylases
|
